Charles Ryan, MD, and Oliver Sartor, MD discuss bone health in the treatment of prostate cancer and then transition to discuss the novel theranostic opportunities that are in development for the treatment of prostate cancer including Lutetium-177 PSMA and Actinium PSMA-225. Lastly, they have a concise conversation about DNA mutations in prostate cancer and the implications of germ-line and somatic molecular diagnostic testing.

Biographies:
Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research

Charles J. Ryan, MD

Related Content:

PROPHECY - A Prospective Trial of Circulating Tumor Cell AR-V7 Detection in mCRPC with Abiraterone or Enzalutamide